Das infantile Hämangiom: Pathogenese und Wirkmechanismus von Propranolol

Abstract

SummaryInfantile hemangioma (IH) is the most common benign tumor of childhood, with a prevalence of 4 % to 10 %. It is characterized by a proliferative rapid growth phase, which starts after a few weeks of life, followed by a slow regression phase. In IH cases that are potentially disfiguring or life-threatening (10 % to 15 % of all cases), systemic therapy should be promptly initiated. Data source: The present study reviews published scientific articles available in reliable electronic databases. Selected were all studies that evaluated the pathogenesis of IH and the mechanisms of action of propranolol. Conclusions: The pathogenesis of IH has not been fully elucidated. Studies show that, in the proliferative phase of IH, there is an imbalance of angiogenic factors and an increase in the levels of vascular endothelial growth factor and matrix-metalloproteinases 2 and 9. In the regression phase, the levels of these factors decrease, whereas

Identification of novel potential biomarkers in infantile hemangioma via weighted gene co-expression network analysis

“…Infantile hemangioma (IH) is the most common benign tumor of the vascular endothelium in children with a prevalence of 4–10% of children younger than 12 months [ 1 – 3 ]. It is most frequently found in the head and neck around 60% of the cases, followed by the trunk and extremities.…”

Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells

“…Infantile hemangioma is one of the most common benign tumors affecting children, occurring in 4–10% of all infants and ~10–15% require medical treatment (1,2). The tumors consist of endothelial cells and stromal components, including fibroblasts, pericytes and mast cells (3,4).…”

“…Before 2008, various therapies have been established to treat infantile hemangioma, including cortisone, vincristine, interferon-α and lasertherapy; however, these therapeutic treatments have been demonstrated to be associated with potentially severe adverse side effects (5). Following reports on antiproliferative effects of propranolol by Léauté-Labrèze et al (6) in 2008, various studies have been performed investigating the mechanisms by which propranolol induces the involution of hemangiomas (1,2). Propranolol is a non-selective β-blocker used worldwide as the first-line therapy for hemangiomas (5).…”